Publication

Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study

Beugeling, M., Amssoms, K., Cox, F., De Clerck, B., Van Gulck, E., Verwoerd, J., Kraus, G., Roymans, D., Baert, L., Frijlink, H. W. & Hinrichs, W., Oct-2019, In : Pharmaceutics. 11, 10, 18 p., 510.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Beugeling, M., Amssoms, K., Cox, F., De Clerck, B., Van Gulck, E., Verwoerd, J., ... Hinrichs, W. (2019). Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study. Pharmaceutics, 11(10), [510]. https://doi.org/10.3390/pharmaceutics11100510

Author

Beugeling, Max ; Amssoms, Katie ; Cox, Freek ; De Clerck, Ben ; Van Gulck, Ellen ; Verwoerd, Jeroen ; Kraus, Guenter ; Roymans, Dirk ; Baert, Lieven ; Frijlink, H.W. ; Hinrichs, Wouter. / Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice : A Proof of Concept Study. In: Pharmaceutics. 2019 ; Vol. 11, No. 10.

Harvard

Beugeling, M, Amssoms, K, Cox, F, De Clerck, B, Van Gulck, E, Verwoerd, J, Kraus, G, Roymans, D, Baert, L, Frijlink, HW & Hinrichs, W 2019, 'Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study', Pharmaceutics, vol. 11, no. 10, 510. https://doi.org/10.3390/pharmaceutics11100510

Standard

Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice : A Proof of Concept Study. / Beugeling, Max; Amssoms, Katie; Cox, Freek; De Clerck, Ben; Van Gulck, Ellen; Verwoerd, Jeroen; Kraus, Guenter; Roymans, Dirk; Baert, Lieven; Frijlink, H.W.; Hinrichs, Wouter.

In: Pharmaceutics, Vol. 11, No. 10, 510, 10.2019.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Beugeling M, Amssoms K, Cox F, De Clerck B, Van Gulck E, Verwoerd J et al. Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study. Pharmaceutics. 2019 Oct;11(10). 510. https://doi.org/10.3390/pharmaceutics11100510


BibTeX

@article{873586d07e844d36be4dac4a6904e51a,
title = "Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study",
abstract = "Currently, there is an increasing interest to apply pre-fusion (pre-F) protein of respiratory syncytial virus (RSV) as antigen for the development of a subunit vaccine. A pre-F-containing powder would increase the flexibility regarding the route of administration. For instance, a pre-F-containing powder could be incorporated into a single-injection system releasing a primer, and after a lag time, a booster. The most challenging aspect, obtaining the booster after a lag time, may be achieved by incorporating the powder into a core encapsulated by a nonporous poly(dl-lactic-co-glycolic acid) (PLGA) shell. We intended to develop a stable freeze-dried pre-F-containing powder. Furthermore, we investigated whether incorporation of this powder into the core-shell implant was feasible and whether this system would induce a delayed RSV virus-neutralizing antibody (VNA) response in mice. The developed pre-F-containing powder, consisting of pre-F in a matrix of inulin, HEPES, sodium chloride, and Tween 80, was stable during freeze-drying and storage for at least 28 days at 60 degrees C. Incorporation of this powder into the core-shell implant was feasible and the core-shell production process did not affect the stability of pre-F. An in vitro release study showed that pre-F was incompletely released from the core-shell implant after a lag time of 4 weeks. The incomplete release may be the result of pre-F instability within the core-shell implant during the lag time and requires further research. Mice subcutaneously immunized with a pre-F-containing core-shell implant showed a delayed RSV VNA response that corresponded with pre-F release from the core-shell implant after a lag time of approximately 4 weeks. Moreover, pre-F-containing core-shell implants were able to boost RSV VNA titers of primed mice after a lag time of 4 weeks. These findings could contribute to the development of a single-injection pre-F-based vaccine containing a primer and a booster.",
keywords = "biphasic pulsatile release, controlled release, freeze-dried powder, fusion protein, poly(dl-lactic-co-glycolic acid), pre-fusion, respiratory syncytial virus, single-injection vaccine, POLY(LACTIDE-CO-GLYCOLIDE) IMPLANTS, VACCINE POWDER, STABILIZATION, MECHANISMS, CHALLENGES, COMPLETENESS, FORMULATIONS, DEGRADATION, INSTABILITY, TECHNOLOGY",
author = "Max Beugeling and Katie Amssoms and Freek Cox and {De Clerck}, Ben and {Van Gulck}, Ellen and Jeroen Verwoerd and Guenter Kraus and Dirk Roymans and Lieven Baert and H.W. Frijlink and Wouter Hinrichs",
year = "2019",
month = "10",
doi = "10.3390/pharmaceutics11100510",
language = "English",
volume = "11",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "MDPI AG",
number = "10",

}

RIS

TY - JOUR

T1 - Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice

T2 - A Proof of Concept Study

AU - Beugeling, Max

AU - Amssoms, Katie

AU - Cox, Freek

AU - De Clerck, Ben

AU - Van Gulck, Ellen

AU - Verwoerd, Jeroen

AU - Kraus, Guenter

AU - Roymans, Dirk

AU - Baert, Lieven

AU - Frijlink, H.W.

AU - Hinrichs, Wouter

PY - 2019/10

Y1 - 2019/10

N2 - Currently, there is an increasing interest to apply pre-fusion (pre-F) protein of respiratory syncytial virus (RSV) as antigen for the development of a subunit vaccine. A pre-F-containing powder would increase the flexibility regarding the route of administration. For instance, a pre-F-containing powder could be incorporated into a single-injection system releasing a primer, and after a lag time, a booster. The most challenging aspect, obtaining the booster after a lag time, may be achieved by incorporating the powder into a core encapsulated by a nonporous poly(dl-lactic-co-glycolic acid) (PLGA) shell. We intended to develop a stable freeze-dried pre-F-containing powder. Furthermore, we investigated whether incorporation of this powder into the core-shell implant was feasible and whether this system would induce a delayed RSV virus-neutralizing antibody (VNA) response in mice. The developed pre-F-containing powder, consisting of pre-F in a matrix of inulin, HEPES, sodium chloride, and Tween 80, was stable during freeze-drying and storage for at least 28 days at 60 degrees C. Incorporation of this powder into the core-shell implant was feasible and the core-shell production process did not affect the stability of pre-F. An in vitro release study showed that pre-F was incompletely released from the core-shell implant after a lag time of 4 weeks. The incomplete release may be the result of pre-F instability within the core-shell implant during the lag time and requires further research. Mice subcutaneously immunized with a pre-F-containing core-shell implant showed a delayed RSV VNA response that corresponded with pre-F release from the core-shell implant after a lag time of approximately 4 weeks. Moreover, pre-F-containing core-shell implants were able to boost RSV VNA titers of primed mice after a lag time of 4 weeks. These findings could contribute to the development of a single-injection pre-F-based vaccine containing a primer and a booster.

AB - Currently, there is an increasing interest to apply pre-fusion (pre-F) protein of respiratory syncytial virus (RSV) as antigen for the development of a subunit vaccine. A pre-F-containing powder would increase the flexibility regarding the route of administration. For instance, a pre-F-containing powder could be incorporated into a single-injection system releasing a primer, and after a lag time, a booster. The most challenging aspect, obtaining the booster after a lag time, may be achieved by incorporating the powder into a core encapsulated by a nonporous poly(dl-lactic-co-glycolic acid) (PLGA) shell. We intended to develop a stable freeze-dried pre-F-containing powder. Furthermore, we investigated whether incorporation of this powder into the core-shell implant was feasible and whether this system would induce a delayed RSV virus-neutralizing antibody (VNA) response in mice. The developed pre-F-containing powder, consisting of pre-F in a matrix of inulin, HEPES, sodium chloride, and Tween 80, was stable during freeze-drying and storage for at least 28 days at 60 degrees C. Incorporation of this powder into the core-shell implant was feasible and the core-shell production process did not affect the stability of pre-F. An in vitro release study showed that pre-F was incompletely released from the core-shell implant after a lag time of 4 weeks. The incomplete release may be the result of pre-F instability within the core-shell implant during the lag time and requires further research. Mice subcutaneously immunized with a pre-F-containing core-shell implant showed a delayed RSV VNA response that corresponded with pre-F release from the core-shell implant after a lag time of approximately 4 weeks. Moreover, pre-F-containing core-shell implants were able to boost RSV VNA titers of primed mice after a lag time of 4 weeks. These findings could contribute to the development of a single-injection pre-F-based vaccine containing a primer and a booster.

KW - biphasic pulsatile release

KW - controlled release

KW - freeze-dried powder

KW - fusion protein

KW - poly(dl-lactic-co-glycolic acid)

KW - pre-fusion

KW - respiratory syncytial virus

KW - single-injection vaccine

KW - POLY(LACTIDE-CO-GLYCOLIDE) IMPLANTS

KW - VACCINE POWDER

KW - STABILIZATION

KW - MECHANISMS

KW - CHALLENGES

KW - COMPLETENESS

KW - FORMULATIONS

KW - DEGRADATION

KW - INSTABILITY

KW - TECHNOLOGY

U2 - 10.3390/pharmaceutics11100510

DO - 10.3390/pharmaceutics11100510

M3 - Article

VL - 11

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 10

M1 - 510

ER -

ID: 99965451